Golden Hour Pharma
Golden HourPharma
Vast institutional medical stockpile warehouse interior with rows of unbranded pharmaceutical storage cases on industrial shelving, warm golden light from above
Emergency Medicine

Emergency Medical Stockpiles: What Governments Actually Store

A benchmark piece on what governments actually hold in their national medical stockpiles — SNS, rescEU, NESS, RANET — and the procurement gap across MENA, Africa, and Latin America.

✦Golden Hour Pharma✦May 5, 2026✦14 min read

Opening

Most countries say they have a national medical stockpile. Far fewer can produce a current line-item list of what is in it.

The gap is not a clerical accident. It is the consequence of three converging realities. National stockpile composition is treated as a security matter, and most countries deliberately limit public disclosure. The medicines that matter most in a crisis — radiological antidotes, broad-spectrum antibiotics, smallpox vaccine, blood products — are exactly the categories that politicians least want benchmarked. And the global authorities that publish guidance on what to stockpile rarely publish what their member states actually hold.

The result is a procurement environment in which ministries of health across MENA, Africa, and Latin America have limited public reference points to compare their own holdings against. This article assembles what is publicly documented across the major national and regional stockpiles, identifies the categories that consistently appear, and maps the gaps that are most consequential for institutional buyers in those regions.

This is a benchmark piece, not an audit. Procurement officers should treat it as a starting point for internal review, not as a substitute for the supplier dossier and regulatory analysis that any individual purchase requires.

Why National Stockpiles Exist — And Why the Framework Changed in 2023

The modern policy framework for national medical stockpiles is set by the World Health Organization's January 2023 publication National Stockpiles for Radiological and Nuclear Emergencies: Policy Advice (ISBN 978-92-4-006787-5), which superseded the 2007 guidance. The new policy makes three positions explicit.

Every country is expected to maintain a national stockpile of medicines for radiological and nuclear emergencies — or to have access through a binding regional arrangement. The recommended formulary includes stable iodine (Potassium Iodide or Potassium Iodate), Prussian Blue, calcium-DTPA and zinc-DTPA, myeloid cytokines for hematopoietic acute radiation syndrome, antiemetics, antidiarrheals, broad-spectrum antibiotics, and blood products. The stockpile must be built before the event, not procured during it.

The same week as the WHO policy update, the Critical Medicines List for radiation and nuclear emergencies was refreshed. Both Potassium Iodide and Prussian Blue (potassium ferric hexacyanoferrate) appear on the WHO Model List of Essential Medicines. Prussian Blue has been on the list since 1989, despite its orphan-drug status — a status that reflects the rarity of the cesium-contamination events it treats, not its strategic importance. The WHO position is that every country should hold both, regardless of population disease burden.

The IAEA's 2024 publication Generic Procedures for Medical Response During a Nuclear or Radiological Emergency mirrors the WHO list. The Strategic National Stockpile of the United States, the EU rescEU CBRN reserve, and Canada's National Emergency Strategic Stockpile all map to the same core formulary. There is no longer any serious analytical disagreement about what a radiological-readiness stockpile should contain. The question — for procurement teams in regions that have not yet built one — is how.

Inside the U.S. Strategic National Stockpile

The Strategic National Stockpile (SNS) is the largest, most documented, and most studied national medical stockpile in the world. It is managed by the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services.

Public valuations place the managed inventory above 7 billion U.S. dollars, with additional appropriations in the COVID-19 era pushing the total higher. A Government Accountability Office report (GAO-23-106210) noted that HHS obligated approximately 6.1 billion U.S. dollars in pandemic-era relief funds toward stockpile expansion. By any measure, the SNS is the largest single repository of medical countermeasures in the world.

Sources: U.S. ASPR ; GAO-23-106210 ; Congressional Research Service R47400

The SNS is organised into product categories rather than disease silos. Public disclosures and Congressional Research Service analyses (notably CRS R47400) confirm the following composition:

  • Broad-spectrum oral and intravenous antibiotics, including ciprofloxacin and doxycycline at quantities sufficient for mass post-exposure prophylaxis (anthrax response is a documented design driver)
  • Smallpox vaccine: pre-COVID public reports cited approximately 300 million treatment courses across ACAM2000 and JYNNEOS formulations
  • Anthrax vaccine sufficient, in published estimates, for response to a multi-city incident
  • Antivirals for influenza pandemic response
  • Intravenous fluids, airway equipment, ventilators, and trauma supplies
  • The CHEMPACK programme: 1,960 chemical countermeasure containers prepositioned across approximately 1,340 sites in all states and territories. Each hospital pack treats roughly 1,000 nerve-agent casualties; each EMS pack treats approximately 454.
  • The radiation formulary: Potassium Iodide, Prussian Blue, Ca-DTPA and Zn-DTPA, and the FDA-approved myeloid cytokines (filgrastim, pegfilgrastim, sargramostim) for hematopoietic acute radiation syndrome

The SNS is not a single warehouse. It is a distributed network of strategically placed depots designed to deliver medical countermeasures within 12 hours of an authorised request. CHEMPACK pre-positioning is a deliberate decision to trade central control for response speed in time-critical incidents.

Source: U.S. CDC CHEMPACK Program

The WHO Recommendation — And the WHO's Own Operational Stockpiles

The WHO is both the policy-setting authority for national stockpiles and the operator of several of its own. These functions are sometimes confused.

On the policy side, the WHO Critical Medicines List and the 2023 stockpile policy define what a national stockpile should hold. Member states are expected to follow the recommended formulary, calibrated to their population and threat profile.

On the operational side, the WHO holds approximately 35 million doses of smallpox vaccine for outbreak and bioterrorism response. The International Coordinating Group on Vaccine Provision (ICG) — a partnership between the WHO, UNICEF, IFRC, and Médecins Sans Frontières — manages global emergency stockpiles for oral cholera vaccine, yellow fever vaccine, and meningococcal vaccine. UNICEF runs the operational logistics for several of these stockpiles on behalf of the ICG.

These global stockpiles are not a substitute for national procurement. They are deployed only when a country has exhausted its own resources or when a multi-country outbreak triggers ICG mobilisation. Member states that rely on the WHO and ICG as their primary radiological or pandemic stockpile are operating outside the framework the WHO itself recommends.

EU rescEU and HERA — The Regional Model

The European Union has built the most sophisticated multi-national stockpile architecture outside the United States. The architecture is twofold.

The European Health Emergency Preparedness and Response Authority (HERA), established in 2021, sets policy and coordinates strategic procurement across EU Member States. The rescEU strategic reserve, managed under the EU Civil Protection Mechanism, is the operational stockpile.

Public figures place the rescEU programme at approximately 540.5 million euros in initial budget allocation, with 22 stockpiles distributed across 16 Member States. By 2024, 17 of those stockpiles were fully operational. The decontamination reserve is hosted by Croatia, Germany, and Spain on a 66.7 million euro EU-financed allocation.

The first dedicated CBRN strategic reserve was established in Finland in January 2023, with an allocation of approximately 242 million euros. As one of the first operational tests of the network, the EU procured roughly 3 million Potassium Iodide tablets and delivered them to Ukraine through the Civil Protection Mechanism, with France and Spain leading the supply.

The rescEU model is informative for any region considering pooled stockpiling. It demonstrates that a coordinated regional reserve, supported by central financing and distributed hosting, can scale beyond what any single country could afford on its own. The African Union's pharmaceutical manufacturing strategy, MENA's regional emergency coordination structures, and Latin American regional health bodies all have parallel pathways available, even if implementation lags policy.

Sources: European Commission — rescEU strategic reserve ; HERA

IAEA RANET, REMPAN, and the Radiation-Emergency Layer

Radiation emergencies have a dedicated international response architecture that sits alongside national stockpiles. The IAEA's Response and Assistance Network (RANET) operates under the Convention on Assistance in the Case of a Nuclear Accident or Radiological Emergency. It is paired with the WHO's Radiation Emergency Medical Preparedness and Assistance Network (REMPAN) and the Inter-Agency Committee on Radiological and Nuclear Emergencies (IACRNE).

RANET's recommended national stockpile mirrors the WHO 2023 formulary almost exactly: stable iodine, Prussian Blue, Ca-DTPA and Zn-DTPA, myeloid cytokines, antiemetics, broad-spectrum antibiotics. The added value of RANET is mutual assistance — countries that have signed the convention can request and receive specialised medical resources from other signatories during an emergency.

RANET membership does not replace national stockpiling. It supplements it. A country with no national radiological countermeasure inventory cannot expect international assistance to arrive within the time window that matters most.

National Examples Beyond the United States

Canada's National Emergency Strategic Stockpile (NESS) is managed by the Public Health Agency of Canada. As of 31 March 2023, the inventory was approximately 60 percent medical supplies, 20 percent medical equipment, and less than 20 percent medical countermeasures, with social-service supplies under 1 percent. Holdings are distributed across 10 federal warehouses and approximately 1,300 prepositioned supply centres, with a 24-hour deployment target. The NESS Comprehensive Management Plan, published by Health Canada, is among the most detailed publicly available national stockpile blueprints.

Source: Public Health Agency of Canada — National Emergency Strategic Stockpile

The United Kingdom's pandemic stockpile — pre-COVID — held approximately 400 million PPE items in a 373,000 square foot Merseyside facility, with 48,998 pallets and more than 500 million individual items. Antibiotics for secondary bacterial pneumonias were included. Following the COVID-19 review, the UK Health Security Agency announced a 1 billion pound expansion of pandemic preparedness, including stockpile modernisation.

Source: UK National Audit Office — The supply of personal protective equipment during the COVID-19 pandemic

Japan, post-Fukushima, restructured its stable-iodine distribution policy. Fukushima Prefecture's emergency cache held approximately 400,000 KI tablets at the time of the 2011 disaster. The town of Miharu — one of the few jurisdictions to actually distribute KI to its population — reached 94.9 percent of households, of which 63.5 percent of recipients ingested the medication. The U.S. Embassy in Tokyo separately requested liquid KI from the U.S. Strategic National Stockpile to protect U.S. citizens in Japan; the consignment was prepared but ultimately not deployed. The lasting post-Fukushima reform was a shift to pre-distributing stable iodine to populations within precautionary action zones, rather than relying on central distribution at the moment of an event.

Source: Sase E, Kato S, Takahashi Y, et al. "Stable Iodine Distribution Among Children After the 2011 Fukushima Nuclear Disaster in Japan: An Observational Study." Journal of Clinical Endocrinology & Metabolism, 2019. DOI: 10.1210/jc.2018-01473

France contributes to the EU's KI delivery to Ukraine and hosts rescEU components. National civil protection includes pre-distributed KI to populations within the precautionary action zones around nuclear installations, a policy extended in September 2019 to a 20-kilometre radius around 19 plants.

Source: European Nuclear Safety Regulators Group — France country profile

Across other major regions, specific national stockpile composition is largely classified — a pattern consistent with the security-driven non-disclosure observed in most countries. Governments across MENA coordinate on CBRN preparedness through regional exercises and emergency centres, but stockpile composition is not publicly disclosed. Several ministries of health in the region have issued emergency-readiness guidelines to hospitals during recent escalations without disclosing specific inventories.

The Seven Categories Every Modern Stockpile Holds

Across the systems documented above, seven categories appear consistently. Procurement officers can use this list as a structural benchmark when reviewing or building a national stockpile.

  • Stable iodine — Potassium Iodide and Potassium Iodate, in WHO-aligned dose tiers (16 mg, 32 mg, 65 mg, 130 mg)
  • Decorporation agents — Prussian Blue (ferric hexacyanoferrate) for cesium and thallium; Ca-DTPA and Zn-DTPA for transuranic elements
  • Myeloid cytokines — for hematopoietic acute radiation syndrome (filgrastim, pegfilgrastim, sargramostim are the FDA-approved options)
  • Broad-spectrum antibiotics — particularly fluoroquinolones (ciprofloxacin) and tetracyclines (doxycycline) for anthrax post-exposure prophylaxis and febrile neutropenia in radiation casualties
  • Antivirals and vaccines — pandemic influenza antivirals, smallpox vaccine, and the ICG-managed cholera, yellow fever, and meningococcal stockpiles
  • Symptomatic-care medicines — antiemetics, antidiarrheals, IV fluids, electrolyte solutions
  • Blood products and consumables — platelets, packed red cells, irradiated leukocyte-reduced products for radiation casualties; mass-casualty surgical and burn-care consumables

A national stockpile that omits any of these categories is structurally incomplete. The omission may be appropriate for a specific country's threat profile — a landlocked nation with no nuclear infrastructure may reasonably rank radiation antidotes lower than antibiotics — but the omission should be a documented decision, not an oversight.

The MENA, Africa, and Latin America Gap

The most consequential procurement gaps are not in the countries with mature stockpiles. They are in the regions where the framework exists on paper but has not yet been built out in practice.

In Africa, more than 70 percent of medicines are imported, primarily from external manufacturing hubs in Asia. During the COVID-19 emergency, high-resource economies prioritised domestic stockpiling, leaving African systems exposed for prolonged periods. The African Union's Pharmaceutical Manufacturing Plan for Africa, paired with Africa CDC's institutional build-out, targets domestic vaccine and therapeutic capacity by 2040. In the interim, national radiological and pandemic stockpiles depend on imports — and on supplier relationships that are reliable enough to clear regulatory and lead-time hurdles in advance of the event.

Source: Brookings Institution, Africa Growth Initiative — "Figure of the week: Africa's trade in pharmaceuticals" (2022)

In MENA, several governments have well-resourced civil protection structures and regional coordination, but stockpile composition is rarely disclosed and access for institutional procurement teams elsewhere in the region is inconsistent. North African economies face the same import-dependence pattern as sub-Saharan Africa.

In Latin America, pandemic preparedness reviews have repeatedly identified stockpiling of antivirals and vaccines as a documented weak link. Radiological readiness, where addressed at all, tends to focus on the small number of regional countries operating nuclear power reactors, without comprehensive coverage of dirty-bomb or orphan-source scenarios.

Source: IAEA Power Reactor Information System (PRIS) — Operational Reactors by Country

Across all three regions, the practical procurement constraint is the same: limited access to WHO-aligned, FDA-approved, regulator-grade supply for the categories that the global benchmarks recommend. Stable iodine, Prussian Blue, and DTPA-class decorporation agents are not produced domestically in most of these markets. Reliable institutional supply through qualified manufacturers and dossier-supported distribution is the only viable path.

Golden Hour Pharma supplies the three core pillars of the radiological decorporation stockpile — Potassium Iodide (in 32 mg, 65 mg, and 130 mg strengths), Potassium Iodate as a long-shelf-life alternative for tropical climates, and Prussian Blue (ferric hexacyanoferrate) for cesium and thallium decorporation — anchored to WHO-aligned cGMP manufacturing, batch validation, certificate-of-analysis support, and dossier readiness for institutional review. The intent is to give procurement officers in MENA, Africa, and Latin America a credible supplier pathway aligned to the same international benchmarks documented in this article.

Conclusion

National medical stockpiles are the silent infrastructure of public health. They are visible only when they fail. The countries that have built them — the United States, the European Union member states, Canada, the United Kingdom, Japan, France — built them in peacetime, on multi-year horizons, with stable financing and disciplined procurement. The countries that have not yet built them are operating with the same threat surface and a smaller margin for error.

The WHO 2023 framework, the IAEA 2024 procedures, and the SNS, rescEU, and NESS public records together provide a procurement officer with the most complete public benchmark available today. The composition of a serious national stockpile is no longer a matter of expert disagreement. It is a matter of execution.

For procurement teams ready to move from policy review to supply planning, the next step is a structured review of existing inventory against the seven-category benchmark above, followed by an audit of supplier qualifications, regulatory pathways, and lead times. To request a procurement dossier or to commission a category-specific supply assessment for the radiological countermeasure pillars, contact the Golden Hour Pharma institutional supply team.

Sources

Policy framework

United States — Strategic National Stockpile

European Union — rescEU and HERA

Canada — National Emergency Strategic Stockpile

United Kingdom — pandemic stockpile

Japan — Fukushima KI distribution

  • Sase E, Kato S, Takahashi Y, et al. Stable Iodine Distribution Among Children After the 2011 Fukushima Nuclear Disaster in Japan: An Observational Study. Journal of Clinical Endocrinology & Metabolism, 2019. DOI: 10.1210/jc.2018-01473. https://academic.oup.com/jcem/article/104/5/1658/5235616

France — KI pre-distribution policy

Africa — pharmaceutical import dependency

Latin America — operational nuclear power capacity

General reference

  • Council on Foreign Relations. The State of U.S. Strategic Stockpiles. Backgrounder.
Pharmaceutical Preparedness

Ready When It Matters Most

Golden Hour Pharma supports healthcare systems, institutions, and emergency preparedness efforts with critical medicines, strategic supply planning, and responsive pharmaceutical support across high-risk environments.

Read More Insights Visit Golden Hour Pharma

WHO-GMP Certified · Strategic Stockpiling · Emergency Supply